Undisclosed TNFα inhibitor / Arcus Biosci - LARVOL DELTA

Arcus Provides Update on...Emerging Inflammation and Immunology Portfolio (Arcus Biosciences Press Release) - "Arcus expects to advance two potentially best-in-class small molecule inhibitors into the clinic in the timeframes noted below: 2026: MRGPRX2, a potential treatment for atopic dermatitis and chronic spontaneous urticaria; and Late 2026 - early 2027: TNF, a potential treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease (such as ulcerative colitis)."

New trial • Atopic Dermatitis • Chronic Spontaneous Urticaria • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis • Ulcerative Colitis

Arcus..discovery and preclinical programs disclosed today provide multiple opportunities to advance into the clinic in 2026. (Arcus Biosciences Press Release) - "Potential new drug candidates include: MRGPRX2 small-molecule inhibitor, a potential treatment for atopic dermatitis and chronic spontaneous urticaria; TNF-a (TNFR1) small-molecule inhibitor, a potential treatment for rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (such as ulcerative colitis); CCR6 small-molecule inhibitor, a potential treatment for psoriasis; CD89 monoclonal antibody, a potential treatment for RA; CD40L small-molecule inhibitor, a potential treatment for multiple sclerosis and systemic lupus erythematosus"

New molecule • Atopic Dermatitis • Chronic Spontaneous Urticaria • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Ulcerative Colitis